The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 09, 2022

Filed:

Oct. 23, 2018
Applicant:

Mati Therapeutics Inc., Austin, TX (US);

Inventors:

Eugene de Juan, Jr., San Francisco, CA (US);

Cary Reich, Los Gatos, CA (US);

Stephen Boyd, Murrieta, CA (US);

Hanson S. Gifford, III, Woodside, CA (US);

Mark Deem, Mountain View, CA (US);

Assignee:

Mati Therapeutics Inc., Austin, TX (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 9/00 (2006.01); A61F 9/007 (2006.01); A61F 9/00 (2006.01); A61K 31/216 (2006.01); A61K 31/5575 (2006.01); A61K 47/34 (2017.01); A61K 31/573 (2006.01); A61K 31/557 (2006.01); A61K 31/55 (2006.01); A61L 31/16 (2006.01); A61K 31/215 (2006.01); A61K 9/06 (2006.01);
U.S. Cl.
CPC ...
A61K 9/0051 (2013.01); A61F 9/0017 (2013.01); A61F 9/0026 (2013.01); A61F 9/00772 (2013.01); A61F 9/00781 (2013.01); A61K 9/00 (2013.01); A61K 9/0017 (2013.01); A61K 9/06 (2013.01); A61K 31/215 (2013.01); A61K 31/216 (2013.01); A61K 31/55 (2013.01); A61K 31/557 (2013.01); A61K 31/5575 (2013.01); A61K 31/573 (2013.01); A61K 47/34 (2013.01); A61L 31/16 (2013.01); A61F 2220/0008 (2013.01); A61F 2250/0067 (2013.01); A61F 2250/0087 (2013.01);
Abstract

An implant for insertion into a punctum of a patient comprises a body. The body has a distal end, a proximal end, and an axis therebetween. The distal end of the body is insertable distally through the punctum into the canalicular lumen. The body comprises a therapeutic agent included within an agent matrix drug core. Exposure of the agent matrix to the tear fluid effects an effective therapeutic agent release into the tear fluid over a sustained period. The body has a sheath disposed over the agent matrix to inhibit release of the agent away from the proximal end. The body also has an outer surface configured to engage luminal wall tissues so as to inhibit expulsion when disposed therein. In specific embodiments, the agent matrix comprises a non-bioabsorbable polymer, for example silicone in a non-homogenous mixture with the agent.


Find Patent Forward Citations

Loading…